Last reviewed · How we verify
Carisbamate in Adult & Pediatric Subjects With Lennox-Gastaut Syndrome
This is an open-label, multi-center study of carisbamate in adult and pediatric subjects with LGS, with single- and multiple-dose PK assessments from Days 1 through 73. There will be a Screening Period of up to 28 days and a Treatment Period of 87 days.
Details
| Lead sponsor | SK Life Science, Inc. |
|---|---|
| Phase | PHASE1 |
| Status | COMPLETED |
| Enrolment | 18 |
| Start date | Thu Feb 07 2019 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Wed Jun 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Lennox Gastaut Syndrome
Interventions
- Carisbamate
Countries
United States